Why CorVel is back on investors’ radar
Fresh commentary on CorVel (CRVL) is drawing attention to its 85.4% return on invested capital and debt free balance sheet, raising questions about how this quality profile lines up with the current share price.
See our latest analysis for CorVel.
CorVel’s recent share price tells a mixed story, with a 13.06% 1 month share price return and a 2.21% 1 day gain contrasting with a 24.74% 3 month share price decline and a 50.65% 1 year total shareholder return decline. This suggests earlier momentum has faded despite renewed interest in its quality metrics.
If this has you reassessing where quality and momentum line up, it could be a good moment to broaden your watchlist with 18 top founder-led companies.
With an estimated intrinsic discount of 45.04% sitting alongside an 85.4% ROIC and a debt free balance sheet, the key question is simple: is CorVel a quality stock on sale, or is the market already pricing in future growth?
Preferred P/E of 25.5x: Is it justified?
CorVel is trading on a P/E of 25.5x, which leaves the shares looking expensive versus the broader US Healthcare industry but cheaper than its peer group average.
The P/E ratio compares the company’s share price to its earnings per share and is a quick way to see how much investors are willing to pay for each dollar of profit. For a business like CorVel, which reports high quality earnings, 19.9% earnings growth over the past year and an 11.2% net profit margin, a higher P/E can sometimes reflect confidence in the durability of those profits.
Where it gets interesting is the comparison points. CorVel’s 25.5x P/E is above the US Healthcare industry average of 22.1x. This implies the market is putting a premium on its earnings. However, it is below the peer average P/E of 50x, which suggests investors are not assigning it the same level of optimism as some closer comparables.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Earnings of 25.5x (ABOUT RIGHT)
However, you still need to weigh risks, such as any slowdown in claims activity or pricing pressure in workers’ compensation and auto liability services.
Find out about the key risks to this CorVel narrative.
Another view on what the market is pricing in
While the 25.5x P/E suggests CorVel is roughly in line with what you might expect for a profitable healthcare name, our DCF model points in a different direction. On that view, the current $52.63 share price sits about 45% below an estimated fair value of $95.76.
The gap between a P/E that looks about right and a DCF that flags potential undervaluation raises a practical question for you as an investor: which signal do you treat as more meaningful for a business with high quality earnings and strong returns on equity?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CorVel for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given this mix of signals, do you feel the market is being too cautious or too optimistic here, and how quickly do you want to firm up your own stance by weighing 2 key rewards and 1 important warning sign?
Looking for more investment ideas?
If you are serious about sharpening your watchlist, do not stop at one stock. Use targeted screeners to surface ideas that match your style before others do.
- Spot potential bargains early by scanning our list of 48 high quality undervalued stocks that pair strong fundamentals with prices that may not fully reflect them yet.
- Prioritize resilience by reviewing 68 resilient stocks with low risk scores that score well on stability metrics and may help smooth out the rougher patches in your portfolio.
- Unearth off-the-radar opportunities with our screener containing 26 high quality undiscovered gems that many investors might not be watching closely yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com